This is a tough time to be a progressive, to be honest. Our policy visions have been narrowed, our economy is ravaged by inflation, the Supreme Court keeps pounding us with right-wing rulings that strip Americans of fundamental rights.
It’s enough to drive us to despair. But it’s also the perfect time to think forward and imagine the society we want a decade, two decades, five decades from now. That’s because setting goals for progress is one of the most important ways to fight despondency and actually achieve something.
So for our August issue, we decided to look over that horizon. We picked nine topics
that we think progressives should push for in the next ten years. We call it Prospects 2032. And we launch the series today.
We didn’t want to pick ideas that already have robust movements behind them, like Medicare for All and a Green New Deal. We wanted to go out further on the ledge, finding new concepts to rally around. We began this a couple weeks ago, when our
managing editor Ryan Cooper made the case against Supreme Court judicial review. And today, staff writer Alex Sammon offers his pitch for public pharma, the government manufacture of affordable prescription drugs, to improve access for everyone and end the profit motive in life-saving care.
We believe that planting the flag on big ideas can expand the conversation and give
progressives a place to aspire to in the future. It takes that kind of commitment to move things forward in a country where change is so hard.
We’ll be running this series all week. We put a lot of work into it. And you can support our work by becoming a member today. All of the reader support we receive funds our editorial mission: illuminating stories about ideas, politics and power.
The American Prospect, Inc.
1225 I Street NW, Suite 600
Washington, DC xxxxxx
United States Copyright (c) 2022 The American Prospect. All rights reserved.
To opt out of American Prospect membership messaging, click here.
To manage your newsletter preferences, click here.
To unsubscribe from all American Prospect emails, including newsletters, click here.
